These results suggest that SHP-2 blockade successfully overcomes adaptive resistance to BRAF and MEK inhibitors in a defined subgroup of ERK-dependent tumors, keeping the possibility open for exploiting this strategy for melanoma treatment. Here, PTPN11 is linked to melanoma.